Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
What Is TB-500? Benefits, Research & Safety
A synthetic version of the naturally occurring peptide Thymosin Beta-4, extensively researched for its roles in tissue repair, cell migration, and angiogenesis.
Also known as:
Thymosin Beta-4 Fragment
TB4-Frag
Tβ4
UK summary: Not a licensed UK medicine. The active fragment of Thymosin Beta-4, studied largely in preclinical animal models. Treated by WADA as prohibited; sold by some online retailers as 'research only'.
Quick Facts
Category
Healing & Recovery
Half-Life
Approximately 2-3 days, allowing for less frequent administration than many peptides
UK Status
Not licensed for human therapeutic use. Available only as a research chemical. Prohibited in competitive sports.
EU Status
Not authorised by EMA for human use. Research compound status in member states.
Overview
TB-500 is a synthetic peptide that replicates the active region of Thymosin Beta-4 (Tβ4), a 43-amino acid protein that is naturally present in virtually all human and animal cells. Thymosin Beta-4 is one of the most abundant intracellular proteins and plays fundamental roles in tissue repair, cell migration, and the formation of new blood vessels.
The peptide sequence of TB-500 corresponds to the active site of Thymosin Beta-4, specifically the region responsible for its actin-binding and cell-migration-promoting properties. This makes TB-500 particularly interesting to researchers studying wound healing, tissue regeneration, and recovery from injury.
TB-500's primary mechanism involves the upregulation of actin, a protein that forms part of the cell's cytoskeleton and is essential for cell motility. By promoting actin production and organisation, TB-500 may enhance the ability of cells to migrate to sites of injury and participate in the healing process.
Research has explored TB-500's potential applications in various contexts including muscle and tendon injuries, cardiac repair following ischemic events, wound healing, and neurological recovery. The peptide has generated particular interest in veterinary medicine and sports medicine research.
TB-500 is classified as a research peptide and is not approved for human therapeutic use. It is prohibited by WADA in competitive sports.
Evidence standards summary
TB-500 — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
DAnimal/cell evidence onlyOverall grade against our evidence grading methodology.
Not a licensed UK medicine. The active fragment of Thymosin Beta-4, studied largely in preclinical animal models. Treated by WADA as prohibited; sold by some online retailers as 'research only'.
02Human evidence grade
ETheoretical / insufficientStrength of evidence from published human trials.
03Preclinical evidence grade
CLimited human evidenceAnimal-model and in-vitro evidence quality.
04Regulatory status
- UK: Not licensed for human therapeutic use. Available only as a research chemical. Prohibited in competitive sports.
- EU: Not authorised by EMA for human use. Research compound status in member states.
- Notes: TB-500 is prohibited by WADA and banned in most competitive sports organisations. It is not approved by the FDA, MHRA, or EMA for human medical use. Any use is at individual risk and should be under medical supervision.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Heals tendons and ligaments faster than physio
- Repairs muscle tears, joint damage, and cardiac tissue
- ‘Gold-standard healing stack’ with BPC-157
- Anti-inflammatory and recovery aid for athletes
07Common internet claims
- Stack with BPC-157 for ‘injury immunity’
- Heals injuries that physio can't fix
- Safe based on animal data
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Accelerates muscle and tendon recovery” | D | No | High | Animal-model evidence suggests effects on cell migration and tissue repair; human evidence for the marketed fragment is lacking. |
| “Heals chronic injuries that physio can't” | E | No | High | There are no UK-approved indications. Robust comparison with conventional rehab does not exist in the literature. |
| “Safe for long-term use” | E | No | High | Long-term human safety is not established. |
| “Permitted for non-tested athletes” | E | No | High | TB-500 is prohibited under WADA at all times. Risk applies even where no testing is currently planned. |
09Safety uncertainty score
High
Limited human safety data; meaningful uncertainty about rare or long-term effects.
10Known adverse signals
- Long-term human safety not characterised
- Theoretical concerns from actin-modulating mechanism
- Sterility / identity risk from grey-market supply
- WADA S2 strict-liability risk for athletes
11Drug-interaction uncertainty
High
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
WADA: Prohibited in sportWADA strict-liability framing applies.
13UK legal position
UK: Sold as 'research only' (UK)
Not licensed for human therapeutic use. Available only as a research chemical. Prohibited in competitive sports.
Read the full UK legal guide → Are peptides legal in the UK?
14EU legal position
Not authorised by EMA for human use. Research compound status in member states.
15What this page cannot tell you
- Whether TB-500 is safe for you as an individual.
- What dose or frequency is appropriate for any human condition.
- Whether the product you might obtain actually contains TB-500.
- Long-term effects of repeated thymosin beta-4 fragment exposure.
16Last reviewed
17Citation quality score
CLimited human evidenceQuality of the sources we cite, graded against the evidence grading methodology.
18Research gaps
- No completed UK / EU human RCTs for any tissue-repair indication.
- Pharmacokinetics in humans poorly characterised.
- Long-term safety unknown.
- Combination studies with BPC-157 in humans absent.
19Safer alternatives / established care pathways
- Evidence-based physiotherapy for tendon, ligament, and muscle injury.
- NICE-recommended licensed treatments for the specific condition.
- Specialist sports-medicine assessment for recurring injury patterns.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is TB-500 a licensed UK medicine?
- What human evidence exists beyond preclinical animal data?
- What is the WADA / UKAD position if I compete in sport?
- Are there licensed treatments for my underlying injury?
- If I'm offered TB-500 by a clinic, what regulator covers that clinic?
Discovery & History
Thymosin Beta-4, the parent molecule of TB-500, was first isolated from the thymus gland in 1966 by Allan Goldstein and colleagues at the Albert Einstein College of Medicine in New York. Initially, research focused on its immunological properties, as the thymus plays a crucial role in immune system development.
Throughout the 1970s and 1980s, further research revealed that Thymosin Beta-4 was not limited to immune tissues but was in fact present in virtually all cell types throughout the body. This ubiquitous distribution suggested functions beyond immune regulation.
The discovery that Thymosin Beta-4 was a major actin-sequestering protein came in the 1990s, fundamentally changing understanding of its biological roles. Researchers found that Tβ4 binds to monomeric actin (G-actin) and prevents its polymerisation, thereby regulating the dynamics of the cellular cytoskeleton.
Subsequent research identified the specific regions of Thymosin Beta-4 responsible for its various biological activities. The synthetic peptide TB-500 was developed to replicate the most active region of the molecule for research purposes.
Thymosin Beta-4 gained attention in veterinary medicine, particularly in horse racing, where it was used (controversially) to promote recovery from injuries. This led to increased scrutiny and its eventual prohibition in competitive sports.
Research continues to explore the therapeutic potential of Thymosin Beta-4 and related peptides, with clinical trials investigating applications in wound healing, cardiac repair, and other regenerative medicine applications.
Mechanism of Action
TB-500 exerts its biological effects through several key molecular mechanisms that work together to promote tissue repair and regeneration:
**Actin Regulation and Cell Migration**
The primary mechanism of TB-500 involves its interaction with actin, a protein fundamental to cell structure and movement. TB-500 binds to monomeric actin (G-actin) and promotes the formation of filamentous actin (F-actin), which is essential for cell motility. By upregulating actin production and organisation, TB-500 enhances the ability of various cell types—including stem cells, fibroblasts, and endothelial cells—to migrate to sites of injury.
**Angiogenesis Promotion**
TB-500 stimulates the formation of new blood vessels (angiogenesis) by promoting endothelial cell migration and capillary-like structure formation. Improved vascularisation at injury sites enhances the delivery of oxygen, nutrients, and reparative cells essential for tissue healing. This angiogenic effect is mediated partly through increased VEGF receptor expression.
**Anti-Inflammatory Properties**
Research suggests that TB-500 possesses anti-inflammatory effects, potentially through modulation of inflammatory cytokine production. By reducing excessive inflammation at injury sites, the peptide may help prevent secondary tissue damage and promote a healing environment.
**Cell Differentiation Effects**
Studies indicate that TB-500 may influence the differentiation of progenitor cells and stem cells toward specific tissue lineages. This effect may be particularly relevant for cardiac repair, where the peptide has shown potential to promote cardiomyocyte regeneration.
**Matrix Metalloproteinase Regulation**
TB-500 appears to modulate the activity of matrix metalloproteinases (MMPs), enzymes involved in the breakdown and remodelling of extracellular matrix during tissue repair. Proper regulation of MMPs is essential for organised healing rather than scar tissue formation.
**Gene Expression Modulation**
Research has demonstrated that TB-500 affects the expression of numerous genes involved in tissue repair, including those related to cell survival, inflammation, and matrix remodelling.
Researched Benefits
Based on preclinical and clinical research findings:
- 1Enhanced wound healing and tissue regeneration in multiple animal models
- 2Improved muscle repair and reduced recovery time following injury
- 3Potential cardiac tissue regeneration following ischemic injury
- 4Anti-inflammatory effects that may reduce secondary tissue damage
- 5Accelerated tendon and ligament healing with improved tissue quality
- 6Enhanced hair follicle growth in dermal wound healing models
- 7Potential neuroprotective effects in models of central nervous system injury
- 8Improved blood vessel formation (angiogenesis) at injury sites
Claim vs Evidence
How popular claims about TB-500 stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Accelerates muscle and tendon recovery” | D | No | High | Animal-model evidence suggests effects on cell migration and tissue repair; human evidence for the marketed fragment is lacking. |
| “Heals chronic injuries that physio can't” | E | No | High | There are no UK-approved indications. Robust comparison with conventional rehab does not exist in the literature. |
| “Safe for long-term use” | E | No | High | Long-term human safety is not established. |
| “Permitted for non-tested athletes” | E | No | High | TB-500 is prohibited under WADA at all times. Risk applies even where no testing is currently planned. |
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | 2-2.5 mg per administration (based on research protocols in literature) |
| Frequency | Twice weekly during initial phase, then weekly for maintenance |
| Duration | 4-8 weeks depending on research application and objectives |
| Notes | These are theoretical protocols extrapolated from research data. No approved human dosing exists. TB-500 is typically administered via subcutaneous or intramuscular injection in research settings. Due to its systemic distribution, injection site is less critical than with some other peptides. Consult a healthcare professional before any use. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (most common in research)
- Intramuscular injection (also frequently studied)
| Half-Life | Stability |
|---|---|
| Approximately 2-3 days, allowing for less frequent administration than many peptides | Relatively stable when lyophilised; should be stored at -20°C for long-term preservation; reconstituted solutions should be refrigerated and used within recommended timeframes |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Injection site reactions including redness, swelling, or temporary discomfort
- Temporary fatigue or lethargy reported by some users
- Head rush or flushing immediately following injection
- Temporary flu-like symptoms in some cases
Rare Risks & Concerns
- Unknown long-term effects in humans due to limited clinical data
- Theoretical concerns regarding effects on cancer growth (promotes cell migration)
- Potential cardiovascular effects requiring further investigation
- Possible immune system effects given thymosin origin
Contraindications
- Active cancer or history of malignancy (promotes angiogenesis and cell migration)
- Pregnancy and breastfeeding (no safety data available)
- Cardiovascular conditions (effects not fully characterised)
- Children and adolescents (no paediatric safety data)
- Immune system disorders (potential for immune modulation)
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed for human therapeutic use. Available only as a research chemical. Prohibited in competitive sports.
🇪🇺 European Union
Not authorised by EMA for human use. Research compound status in member states.
TB-500 is prohibited by WADA and banned in most competitive sports organisations. It is not approved by the FDA, MHRA, or EMA for human medical use. Any use is at individual risk and should be under medical supervision.
Clinical Studies Summary
Thymosin β4 Promotes Cardiac Regeneration and Repair
Research demonstrating that Thymosin Beta-4 activates resident cardiac progenitor cells and promotes cardiomyocyte regeneration following myocardial infarction in animal models.
Nature. 2011;474(7353):640-4View on PubMed
Thymosin Beta 4 and Wound Healing: A Multifunctional Approach
Comprehensive review of Thymosin Beta-4's roles in wound healing, including effects on cell migration, angiogenesis, and tissue remodelling.
Ann N Y Acad Sci. 2012;1270:37-44View on PubMed
Role of Thymosin β4 in Tissue Repair and Regeneration
Overview of Thymosin Beta-4's biological activities and potential therapeutic applications in regenerative medicine.
Expert Opin Biol Ther. 2018;18(4):387-394View on PubMed
Looking for TB-500?
Source research-grade TB-500 from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about TB-500
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is TB-500 a licensed UK medicine?
- What human evidence exists beyond preclinical animal data?
- What is the WADA / UKAD position if I compete in sport?
- Are there licensed treatments for my underlying injury?
- If I'm offered TB-500 by a clinic, what regulator covers that clinic?
UK regulatory & safety context
Related Research Guides
Peptide Comparisons
Combination Protocols
Related Peptides
BPC-157
A pentadecapeptide derived from human gastric juice, extensively researched for its potential tissue repair and regenerative properties across multiple organ systems.
Learn moreGHK-Cu
A naturally occurring copper-binding tripeptide researched for its roles in wound healing, skin regeneration, anti-ageing, and tissue remodelling.
Learn moreThymosin Beta-4
A 43-amino acid peptide naturally present in all cells, fundamental to tissue repair, cell migration, and regeneration processes throughout the body.
Learn more